European Journal of Cancer
Volume 33, Issue 5 , Pages 716-726 , April 1997

Proliferative lifespan checkpoints: Cell-type specificity and influence on tumour biology

References 

  1. Leblond CP. Classification of cell populations on the basis of their proliferative capacity. Natl Cancer Inst Monogr. 1964;14:119–149
  2. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614–636
  3. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism?. Trends Cell Biol. 1995;5:293–297
  4. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalisation of normal human diploid fibroblasts. Mol Cell Biol. 1989;9:3088–3092
  5. Olovnikov AM. A theory of marginotomy: the incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41:181–190
  6. Bacchetti S. Telomere dynamics and telomerase activity in cell senescence and cancer. In: Semin Cell Dev Biol. 7:1996;p. 31–39
  7. Wynford-Thomas D. In vitro models of thyroid cancer. Cancer Surveys. 1993;16:115–134
  8. Potten CS, Loeffler M. Stem-cells—attributes, cycles, spirals, pitfalls and uncertainties—lessons for and from the crypt. Development. 1990;110:1001–1020
  9. Broccoli D, Young JW, De Lange T. Telomerase activity in normal and malignant hematopoietic cells. In: Proc Natl Acad Sci USA. 92:1995;p. 9082–9086
  10. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315–2320
  11. Potten CS, Hume WJ, Reid P, Cairns J. The segregation of DNA in epithelial stem cells. Cell. 1978;15:899–906
  12. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science. 1990;249:1129–1132
  13. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cellderived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994;211:90–98
  14. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 1996;16:859–867
  15. Bryan TM, Reddel RR. SV40-induced immortalization of human cells. Crit Rev Oncol. 1994;5:331 357
  16. Shay JW, Wright WE, Brasiskyte D, Van der Hagen BA. E6 of human papillomavirus type 16 can overcome the Ml stage of immortalisation in human mammary epithelial cells but not human fibroblasts. Oncogene. 1993;8:1407–1413
  17. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene. 1994;9:1885–1889
  18. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16ink4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol. 1995;15:4745–4753
  19. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays. 1995;17:501–508
  20. Thut CJ, Chen J-L, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science. 1995;267:100–105
  21. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994;370:220–223
  22. Sabbatini P, Chiou S-K, Rao L, White E. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol. 1995;15:1060–1070
  23. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect of activated human p53 on nuclear DNA replication. EMBO J. 1995;14:2099–2105
  24. Frebourg T, Barbier N, Kassel J, Ng Y-S, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res. 1992;52:6976–6978
  25. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequencespecific DNA binding function of p53. Cell. 1995;83:237–245
  26. Kulju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res. 1995;217:336–345
  27. Afshari CA, Vojta PJ, Annab LA, Futreal PA, Willard TB, Barrett JC. Investigation of the role of G1/S cell cycle mediators in cellular senescence. Exp Cell Res. 1993;209:231–237
  28. Atadja P, Wong H, Garkavtsev I, Geillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. In: Proc Natl Acad Sci USA. 92:1995;p. 8348–8352
  29. Bond JA, Blaydes JP, Bowson J, Haughton MF, Smith JR, Wynford-Thomas D. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SD11/ WAF1. Cancer Res. 1995;55:2404–2409
  30. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SD11/CIP1/WAF1/ p21 RNA in human cells. Mol Carcinogen. 1994;11:59–64
  31. Tahara H, Sato E, Noda A, Ide T. Increase in expression level of p21sdi1/clp1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene. 1995;10:835–840
  32. Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T. Mol Cell Biol. 1996;16:2402–2407
  33. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 1996;271:499–502
  34. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1 to S phase transition. Mol Cell Biol. 1995;15:2612–2624
  35. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 1995;83:1149–1158
  36. Kearsey JM, Coates PJ, Prescott AR, Warbrick E, Hall PA. Gadd45 is a nuclear cell cycle regulated protein which interacts with p21cip1. Oncogene. 1995;11:1675–1683
  37. White AE, Iivanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 1994;8:666–677
  38. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumour growth and progression in vivo. Cell. 1994;78:703–711
  39. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330
  40. Stein GH, Beeson M, Gordon L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science. 1990;249:666–669
  41. Kamb A. Cell-cycle regulators and cancer. Trends Genet. 1995;11:136–140
  42. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv Cancer Res. 1996;68:67–108
  43. DeLange T. Activation of telomerase in a human tumour. In: Proc Natl Acad Sci USA. 91:1994;p. 2882–2885
  44. Wynford-Thomas D, Bond JA, Wyllie FS, Jones CJ. Does telomere shortening drive selection for p53 mutation in human cancer?. Mol Carcinogen. 1995;12:119–123
  45. Bayne RA, Broccoli D, Taggert MH, Thomson EJ, Farr CJ, Cooke HJ. Sandwiching of a gene within 12kb of a functional telomere and alpha satellite does not result in silencing. Hum Mol Genet. 1994;4:539–546
  46. Broccoli D, Godley LA, Donehower LA, Varmus HE, De Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol. 1996;16:3765–3772
  47. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. In: Proc Natl Acad Sci USA. 92:1995;p. 4818–4822
  48. Rubelj I, Pereira-Smith OM. SV40-transformed human cells in crisis exhibit changes that occur in normal cellular senescence. Exp Cell Res. 1994;211:82–89
  49. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. In: Proc Natl Acad Sci USA. 85:1988;p. 6042–6046
  50. Whitaker NJ, Bryan TM, Bonnefin P, et al. Involvement of RB-1, p53 p16INK4 and telomerase in immortalisation of human cells. Oncogene. 1995;11:971–976
  51. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240–4248
  52. Whittaker NJ, Kidston EL, Reddel RR. Finite lifespan of hybrids formed by fusion of different simian virus 40-immortalised human cell lines. J Virol. 1992;66:1202–1206
  53. Sandhu AK, Hubbard K, Kaur GP, Jha KK, Ozer HL, Athwal RS. Senescence of immortal human fibroblasts by the introduction of normal human chromosome 6. In: Proc Natl Acad Sci USA. 91:1994;p. 5498–5502
  54. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369:574–578
  55. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature. 1995;374:386–388
  56. Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones CJ, Wynford-Thomas D. S phase cell-cycle arrest following DNA damage is independent of the p53/p21WAF1 signalling pathway. Oncogene. 1996;12:1077–1082
  57. Dimri GP, Nakanishi M, Desprez P-Y, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol. 1996;16:2987–2997
  58. Smith JR, Nakanishi M, Robetorye RS, Venable SF, Pereira-Smith OM. Studies demonstrating the complexity of regulation and action of the growth inhibitory gene SDH. Exp Gerontol. 1996;31:327–335
  59. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal × normal cell hybrids. EMBO J. 1996;15:1734–1741
  60. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol. 1996;16:2932–2939
  61. Loughran O, Malliri A, Owens D, et al. Association of CDKN2A/p16INK4a with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene. 1996;13:561–568
  62. Klingelhutz AJ, Barber SA, Smith PP, Dyer K, McDougall JK. Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells. Mol Cell Biol. 1994;14:961–969
  63. Halben CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol. 1991;65:473–478
  64. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalised human mammary epithelial cells. J Virol. 1991;65:6671–6676
  65. Gollahon LS, Shay JVC. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). Oncogene. 1996;12:715–725
  66. Wazer DE, Liu X-L, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. In: Proc Natl Acad Sci USA. 92:1995;p. 3687–3691
  67. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS. Spontaneous in vitro immortalisation of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol. 1995;15:425–432
  68. Shay JW, Van der Haegen BA, Ying Y, Wright WE. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res. 1993;209:45–52
  69. Van der Haegen BA, Shay JW. Immortalization of human mammary epithelial cells by SV40 large T-antigen involves a two step mechanism. In Vitro Cell Dev Biol. 1993;29A:180–182
  70. Taylor-Papadimitriou J, Berdichevsky F, D'Souza B, Burchell J. Human models of breast cancer. In: Lemoine NR, Wright NA editor. The Molecular Pathology of Cancer. Cancer Surveys 16. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1993;p. 59–78
  71. Foster SC, Galloway DA. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary' epithelial cells. Oncogene. 1996;12:1773–1779
  72. Bond JA, Ness GO, Rowson J, Ivan M, White D, Wynford-Thomas D. Spontaneous dedifferentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression. Int J Cancer. 1996;67:563–572
  73. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond D, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen. 1993;7:83–88
  74. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245
  75. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene. 1994;9:281–290
  76. Bond JA, Wyllie FS, Ivan M, Dawson T, Wynford-Thomas D. A variant epithelial subpopulation in normal thyroid with high proliferative capacity in vitro. Mol Cell Endocrinol. 1993;93:175–183
  77. Demers GW, Halben CL, Galloway DA. Elevated wildtype p53 protein levels in human epithelial cell lines immortalised by the human papillomavirus type 16 E7 gene. Virology. 1994;198:169–174
  78. Knight JC, Fletcher CDM. Soft Tissue Tumours. In: Lemoine N, Neoptolemos J, Cooke T editor. Cancer. Oxford: Blackwell Scientific; 1994;p. 262–275
  79. Stratton MR, Moss SD, Warren W, et al. Mutations of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RBI gene. Oncogene. 1990;5:1297–1301
  80. Nicholson RI, Gee JMW. Growth factors and modulation of endocrine response in breast cancer. In: Vedeckis WV editors. Hormones and Cancer. Boston, MA: Birkhauser; 1996;p. 227–264
  81. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor supressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845–855
  82. Mazars R, Spinardi L, BenCheikh M, et al. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992;52:3918–3923
  83. Portella G, Liddell J, Crombie R, et al. Molecular mechanisms of invasion and metastasis during mouse skin tumour progression. Invasion Metastasis. 1994;14:7–16
  84. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim et Biophys Acta. 1994;1198:11–26
  85. Williams DW, Williams ED. The pathology of follicular thyroid epithelial tumours. In: Wynford-Thomas D, Williams ED editor. Thyroid Tumours: Molecular Basis of Pathogenesis. Edinburgh: Churchill Livingstone; 1989;p. 57–65
  86. Wynford-Thomas D. Molecular genetics of thyroid cancer. Trends Endocrinol Metab. 1993;4:224–232
  87. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science. 1996;274:373–376

PII: S0959-8049(97)00064-6

doi: 10.1016/S0959-8049(97)00064-6

European Journal of Cancer
Volume 33, Issue 5 , Pages 716-726 , April 1997

Article Tools